<DOC>
	<DOCNO>NCT01020734</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor bone marrow peripheral blood stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine methotrexate transplant may stop happen . PURPOSE : This phase II trial study well donor stem cell transplant bone marrow transplant work treat patient acute myeloid leukemia remission .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Bone Marrow Transplant Treating Patients With Acute Myeloid Leukemia Remission</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate efficacy allogeneic hematopoietic stem cell transplantation ( HSCT ) bone marrow transplantation ( BMT ) HLA-matched sibling donor , HLA-matched unrelated donor , HLA-mismatched familial donor , term frequency relapse duration remission , patient acute myeloid leukemia ( AML ) either achieve complete remission ( CR1 ) induction chemotherapy experience recurrent AML achieve second CR ( CR2 ) salvage chemotherapy . Secondary - Determine engraftment , donor chimerism , secondary graft failure patient . - Assess acute chronic graft-vs-host disease , immune recovery , infection patient . - Determine transplantation-related mortality , leukemia-free survival , overall survival patient . OUTLINE : - Conditioning chemotherapy allogeneic bone marrow hematopoietic stem cell transplantation ( HSCT ) : After completion induction chemotherapy result complete response ( CR1 ) salvage chemotherapy result CR2 , patient receive 1 follow conditioning regimen transplantation determine age , co-morbidity , type available donor : - 15 55 year age without significant co-morbidity* undergoing HLA-matched sibling bone marrow transplantation ( BMT ) ( BuCy condition ) : Patients receive busulfan IV daily day -7 -4 cyclophosphamide IV 1-2 hour daily day -3 -2 . Patients undergo allogeneic BMT day 0 . - Older 55 year younger 55 year co-morbidity* undergoing HLA-matched sibling BMT ; patient age undergoing HLA-matched unrelated HSCT ; patient age undergoing HLA-mismatched familial donor HSCT ( BuFluATG condition ) : Patients receive busulfan IV daily day -7 -6 , fludarabine phosphate IV 30 minute daily day -7 -2 , anti-thymocyte globulin IV 4 hour daily day -3 -1 , methylprednisolone IV 30 minute daily day -4 -1 . Patients undergo either allogeneic BMT day 0 allogeneic peripheral blood hematopoietic stem cell infusion day 0-1 0-2 . NOTE : *Significant co-morbidity define residual fungal infection lung viscera residual organ toxicity occur induction consolidation chemotherapy . - GVHD prophylaxis : Patients receive cyclosporine orally IV 2-4 hour twice daily begin day -1 follow taper start day 30 ( BuFluATG condition ) day 60 ( BuCy conditioning ) . Patients also receive methotrexate IV day 1 , 3 , 6 last day donor cell infusion . - CNS prophylaxis : Patients receive intrathecal ( IT ) methotrexate condition regimen . Patients receive IT methotrexate every 2 week 3 time transplantation platelet recovery . Patients also receive leucovorin calcium orally IV 4 hour IT methotrexate every 6 hour total 8 dos dose IT methotrexate . After completion study therapy , patient follow every 3 month 3 year annually .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) meet 1 follow criterion : Achieved complete response ( CR1 ) induction chemotherapy Recurrent AML go second CR ( CR2 ) salvage chemotherapy , except undergone prior allogeneic HSCT No acute promyelocytic leukemia acute myeloid leukemia chromosomal change ( 8 ; 21 ) , inv 16 , ( 15 ; 17 ) Must donor available meet one follow criterion : HLAmatched sibling 65 year younger 6/6 HLAmatched unrelated donor ( young 55 year ) antigen A , B , DR HLAmismatched family member ( offspring , parent , haploidentical sibling ) PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Bilirubin &lt; 2.0 mg/dL AST &lt; 3 time upper limit normal Creatinine &lt; 2.0 mg/dL Ejection fraction &gt; 40 % MUGA scan Negative pregnancy test PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia del ( 5q )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
</DOC>